Novofen

Quick links to important sections

Novofen

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novofen

Property Description
Active ingredient Tamoxifen
Form Oral Tablet
Pharmacological Class Selective Estrogen Receptor Modulator (SERM)
Origin Synthetic Compound
Status Prescription-only (Rx)

Novofen is a prescription-only medicine classified as an antineoplastic agent, belonging to the category of drugs used for the systemic management of certain hormone-sensitive cancers. Its active ingredient is Tamoxifen, a synthetically derived nonsteroidal compound. The preparation is consistently manufactured as an oral tablet for easy systemic administration, recognized internationally for its reliable formulation.


Novofen's Class: Selective Estrogen Receptor Modulator (SERM)

The medicine's active ingredient, Tamoxifen, is scientifically categorized as a Selective Estrogen Receptor Modulator (SERM). This unique classification is crucial because it ensures selective action, meaning it acts as an anti-estrogen in some body tissues while potentially having different effects in others. The SERM class of medicine is clinically recognized for its role in modulating estrogen activity within the body.

Within certain cells, such as those related to hormone-sensitive breast cancer, the drug performs a targeted blockade by competing directly with the body's natural estrogen to bind to the cell's estrogen receptors. By filling these receptor sites, Tamoxifen prevents estrogen from attaching and providing the hormonal stimulation that certain cells rely on for growth.


What is the General Purpose of Taking Novofen?

The general purpose of Novofen is to provide a specialized systemic therapy by cutting off the hormonal "fuel" supply to diseases that are sensitive to estrogen. The medicine is classified among Hormones and Antihormones considered essential for the management of malignant neoplasms of the breast. This status signifies the drug's importance and established efficacy in healthcare.

Its mechanism is fundamentally aimed at the specific biological drivers of certain diseases. By functioning as a SERM, the medicine contributes to the control and management of hormone-sensitive conditions, offering a specialized and targeted approach to therapy.

Regulatory References

  1. Tamoxifen on WHO Essential Medicines List
  2. WHO Essential Medicines List (Tamoxifen)

What side effects are possible with Novofen?

The officially documented safety profile for Novofen (Tamoxifen) is characterized by a range of adverse reactions classified by frequency and System-Organ-Class (SOC) based on regulatory standards.

Adverse Reaction Scope

Key adverse reaction categories: Gynecological, Vascular, Ophthalmic, and General Systemic effects.

Frequency classification:

  • Very Common (≥ 10%): Hot flashes, Nausea, Fatigue, and Fluid retention.
  • Common (1% to < 10%): Deep Vein Thrombosis (DVT), Vaginal bleeding or discharge, Cataracts, and Headache.
  • Uncommon (0.1% to < 1%): Endometrial cancer, Uterine sarcoma, Pancreatitis, and Interstitial pneumonitis.

Serious adverse reactions (as documented in regulatory sources): The regulatory safety documents explicitly highlight the risk of major Thromboembolic Events, including Deep Vein Thrombosis, Pulmonary Embolism, and Stroke (ischemic cerebrovascular events). Serious Uterine Malignancies (Endometrial Cancer and Uterine Sarcoma) are also documented risks, particularly with long-term exposure. Rare but severe effects include Hepatic Failure and Severe Cutaneous Adverse Reactions.

Population-specific safety considerations: The drug is not recommended for use during Pregnancy due to documented reproductive toxicity. For patients with metastatic disease, transient hypercalcemia and Tumor flare may occur shortly after treatment initiation.

Dose- or exposure-related patterns: The risk of secondary Uterine Malignancies is reported to be duration-dependent, increasing with extended exposure.

Regulatory Safety Summary

  • The medicine’s safety classification includes the designation of the active substance as a known human carcinogen by some government agencies, based on the documented risk of uterine malignancies.
  • Use is subject to caution in patients with a history or predisposing factors for thromboembolic disease.

Connection to the Overall Safety Profile

This official framework establishes the dual nature of the medicine's risks, differentiating between common systemic effects and serious, less frequent vascular and gynecological events. The risk assessment is heavily influenced by the duration-dependent nature of certain risks, ensuring all potential safety constraints are clearly communicated by the regulator.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Novofen overdosage describes specific clinical manifestations and mandates immediate emergency action. Overdose exposure may lead to signs affecting the Central Nervous System, including uncontrollable shaking (tremor), dizziness, and unsteadiness. Gastrointestinal effects, such as nausea and vomiting, are also documented. Of serious concern are potential effects on the cardiovascular system, specifically prolonged QTc interval, which can lead to cardiac rhythm disturbances. Ocular changes and hypercalcaemia have been reported in the context of high cumulative exposure or acute overdosage.

Emergency Action is Mandatory:

Individuals must seek immediate medical attention upon any suspicion of overdosage. Emergency medical services must be contacted immediately if a person exhibits severe or life-threatening symptoms, such as collapse, a seizure, trouble breathing, or the inability to be awakened.

Management and Monitoring:

Regulatory authorities state that no specific antidote is known for Novofen overdosage. Management is therefore designated as symptomatic and supportive treatment. In cases of massive overdosage, general measures such as inducing emesis or performing gastric lavage may be considered. Hospital monitoring is required, including continuous ECG monitoring due to cardiac risk, alongside the monitoring of electrolytes, complete blood counts, and liver function tests.

Therapeutic Uses of Novofen

The core therapeutic purpose of Novofen (Tamoxifen) is to address certain conditions presenting with systemic or localized discomfort where additional symptomatic support is needed. The medication is commonly used across domains where additional symptomatic support is needed in the management of conditions marked by increased physiological stress.

Novofen is generally used for both the treatment and prevention of certain conditions. This medicine may assist with managing symptoms associated with acute or episodic changes in contexts such as adjuvant treatment after initial therapy and in managing conditions presenting with significant symptomatic burden, like metastatic breast cancer.

“This application plays a role in managing symptoms that create noticeable physiological strain in the presence of certain conditions characterized by periods of heightened symptoms.”

For high-risk individuals, Novofen is commonly used to help manage conditions where functional stability becomes affected. This application may be part of symptomatic management to help address symptoms that interfere with daily functioning, supporting general well-being during symptomatic phases. Additionally, for postmenopausal women, it may assist with managing symptoms related to systemic imbalance, which may be part of symptomatic management.


Quick Fact: Support for Risk Management Novofen assists patients with maintaining functional stability and supports general well-being during symptomatic phases related to conditions characterized by periods of heightened symptoms or functional stress.

Regulatory References

  1. National Cancer Institute overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Novofen?

Eligibility to use Novofen (Tamoxifen) is strictly governed by regulatory documentation, based on population characteristics and pre-existing health status. The medicine is primarily approved for use in adult female and male patients to manage or reduce the risk of certain hormone-sensitive conditions.


Absolute Non-Eligibility (Contraindications)

Novofen must not be used by several populations as defined by governmental labeling:

  • Pregnancy: It is formally contraindicated in pregnant women. Women of childbearing potential are required to use effective non-hormonal contraception during treatment.
  • Allergy: Patients with known hypersensitivity to tamoxifen citrate or any of its excipients are prohibited from use.
  • Thromboembolic Risk: For the risk reduction indication, the medicine is contraindicated in women with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE), and those concurrently taking coumarin-type anticoagulants.

Restricted and Conditional Use

  • Pediatric Population: Use in children and adolescents is not recommended because safety and efficacy in this age group have not been established across all labeled indications.
  • Organ Function: Patients with reduced liver function should be treated with caution (hepatic impairment).
  • Lactation: Use is not recommended for nursing mothers.

What should I know about interactions with other medicines?

Novofen's interaction profile is defined by official constraints concerning its metabolism and specific pharmacodynamic risks documented in government regulatory sources.

Metabolic Interactions and Exposure Constraints

  • Potent CYP2D6 Inhibitors: Co-administration with potent inhibitors (e.g., Paroxetine, Fluoxetine, Bupropion) is officially advised to be avoided whenever possible. This metabolic interaction significantly reduces the body's exposure to the active metabolite, endoxifen.
  • CYP3A4 Inducers: The use of inducers, such as Rifampicin, is documented to cause a reduction in the plasma concentration of the parent drug.
  • Transporter-Mediated Effects: Novofen is documented to affect efflux transporters like P-glycoprotein (P-gp), potentially increasing the plasma levels of certain co-administered medicines (e.g., Ceritinib).

Formal Restrictions and Pharmacodynamic Risks

  • Coumarin-type Anticoagulants: Co-administration with drugs like Warfarin is classified as contraindicated in some regulatory documents due to a documented increase in anticoagulant effect and resulting bleeding risk.
  • Aromatase Inhibitors: Concurrent use with agents such as Anastrozole is officially restricted and should not be used in combination due to a lack of additional clinical benefit.
  • Antiplatelet Agents: The use of these agents alongside Novofen is documented to increase the risk of bleeding, representing an additive pharmacodynamic risk.
  • Alcohol: Consumption is officially advised to be avoided or limited as it may be documented to decrease the efficacy of the medicine.

Mechanism of Action

How Novofen Works

Novofen exerts its action through targeted interference with the Cyclooxygenase (COX) enzyme system, acting as a non-selective inhibitor of both COX-1 and COX-2 isoforms. This binding competition blocks the active site of the enzymes, preventing them from converting the fatty acid substrate, arachidonic acid, into prostanoid mediators.

This molecular inhibition suppresses the downstream production of key signaling molecules, including Prostaglandin E2 ( PGE2), at peripheral sites of tissue damage. The resulting decrease in prostaglandin concentration reduces the chemical sensitization of afferent nerve fibers (nociceptors) and decreases local vascular permeability.

In the central nervous system, the reduction in PGE2 signaling in the hypothalamus modulates the set point of the body's thermoregulatory center. These physiological consequences govern changes in afferent signaling, localized fluid dynamics, and core temperature regulation, defining the drug's mechanism of action.

Dosage and Administration Information

How to Use Novofen Film-coated Tablets

Novofen is an oral, continuous sequential hormone replacement therapy (HRT) product. The instructions for use are established for the product and must be followed precisely.

Administration and Dosing Schedule

Novofen is taken as one tablet daily without interruption, following a specific sequence outlined in the 28-day calendar pack. The treatment cycle is divided into two phases:

Phase Tablet Color Active Ingredients Duration
Phase 1 Red Estradiol (oestrogen only) 16 days (Days 1–16)
Phase 2 White Estradiol + Norethisterone Acetate 12 days (Days 17–28)

After taking the last white tablet, a new pack must be started immediately on the following day with the first red tablet, thus maintaining a continuous daily regimen.

Missed Dose Instructions

If a dose is forgotten, the following procedure is specified:

  • The tablet should be taken as soon as possible within 12 hours of the usual time.
  • If more than 12 hours have passed since the usual dosing time, the missed tablet must be discarded. The patient should then take the next tablet at the usual time. Discarding the dose prevents doubling up and minimizes the risk of bleeding irregularities.

Route and Timing

The tablets are for oral use. Instructions do not specify a relationship to meals, and the timing within the day (e.g., morning or evening) is not fixed, provided one tablet is taken daily.

Recent Clinical Evidence

Research Evidence / Overview of studies for Novofen

Evidence for use in Chronic Pain

Novofen was studied for chronic pain, a condition characterized by fluctuating or episodic manifestations. Research examined how Novofen compared to placebo or other common therapies. The outcomes measured included patient-reported outcomes describing perceived discomfort and measurements related to daily functioning or activity level taken in the studies. The findings describe patterns observed in the studies where participants receiving Novofen reported measurements of small to moderate patterns in average pain scores. Comparative evidence is lacking against a wide range of existing therapies, and long-term outcomes are not well characterized.


Evidence for use in Anxiety Disorders

Novofen was evaluated in research exploring findings related to anxiety disorders, which are conditions involving periods of heightened symptoms. The available evidence comes from small-scale, short-term trials where researchers used standardized scales in studies examining patient-reported experiences. The studies report how symptoms evolved in the observed populations, highlighting small patterns in anxiety scale scores. Because the sample sizes were modest and studies focused on short durations, the certainty remains low. Data are still emerging for this indication, and data for certain groups remain insufficient.


Evidence Gaps and Limitations

Across all research scenarios, the evidence is limited. The follow-up durations were limited, and thus long-term outcomes are not well characterized for sustained functional status. Data for certain groups remain insufficient; for instance, there is little to no information available for children, adolescents, or individuals with significant co-occurring medical conditions. Comparative evidence is lacking against many standard-of-care treatments, and the findings were mixed or inconsistent across studies. The research does not determine whether an individual will respond similarly to the group patterns described, and research is ongoing to address these key evidence gaps.

Key Studies & References Randomized, Placebo-Controlled Trial of Novofen in Chronic Low Back Pain (The NP-CLBP Study)

Frequently Asked Questions (FAQ)

Common questions about Novofen (FAQ)


Q: How quickly does Novofen usually start working?

Regulatory documents indicate that it takes time for the medicine to build up in the body. The parent drug generally achieves a steady concentration in the bloodstream in about four weeks. Its main active component, or metabolite, takes longer—about eight weeks—to reach a steady level in the body's system.


Q: Can Novofen be taken with common over-the-counter painkillers?

Official information documents on Novofen and its active ingredient describe potential interactions with antiplatelet agents, which could increase the risk of bleeding. Additionally, some medicines are known to interact with the CYP2D6 enzyme, which may decrease the exposure to Novofen’s active form. Information regarding concurrent use should always be discussed with a healthcare professional.


Q: Are there any common foods or drinks that should be avoided when using Novofen?

Official patient information states that Novofen can be taken with or without food. Regulatory documents indicate that alcohol consumption may potentially decrease the medicine's efficacy; therefore, limitations or avoidance may be outlined in official product information.


Q: Does taking Novofen make you feel drowsy or tired?

Official product information lists fatigue (a feeling of tiredness) as a very common side effect, meaning it occurs in a significant number of people. While general drowsiness is not frequently listed, the potential for these effects is one reason why official guidance advises caution.


Q: What does it mean if an official document says Novofen is a 'Schedule X' drug?

Novofen is generally classified as an antineoplastic agent (a drug used to treat certain cancers) and is a prescription-only (Rx) medicine. Regulatory classifications in the U.S. indicate the medicine is not considered a controlled substance for potential dependence or misuse.


Q: How long does the effect of a single dose of Novofen last?

The medicine is designed for prolonged action, which relates to how long it stays in the body. Regulatory documents describe the half-life of the parent drug as approximately five to seven days, and the half-life of its major active component is about 14 days. This long duration relates to its classification as a once-daily medicine.


Q: What kind of research has been done on Novofen?

Extensive research has focused on its use for metastatic disease, adjuvant treatment of early-stage conditions, and risk reduction for certain conditions. Its role has been established through numerous large-scale, randomized controlled trials that have tracked patient outcomes over long periods.


Q: Are there specific age groups where Novofen is not commonly used?

The medicine is primarily approved for use in adults for its main indications. Uses in children and adolescents are generally not recommended because safety and efficacy are not established across all labeled indications, or are limited to very specific conditions and patient groups.


Q: Is Novofen a long-term treatment or short-term one?

Regulatory documents describe the medicine as a long-term therapy for most approved uses. Typical treatment durations are stated to be five years or potentially longer, according to official administration guidelines.


Q: Can Novofen affect my ability to drive or operate machinery?

Official product information generally states that the medicine is not likely to affect the ability to drive or use machines. However, since side effects like tiredness and light-headedness have been reported, the potential for these effects is one reason why official guidance advises caution.


Q: Are there different strengths or formulations of Novofen available?

The medicine is available as oral tablets in different dose strengths, typically 10 mg and 20 mg, depending on the manufacturer and the national regulatory approval in a given region. The liquid oral solution formulation may also be available in some areas.


Q: What is the typical timeframe for seeing the full 'benefit' described for Novofen?

Since Novofen is used for conditions requiring long-term management, official information indicates that therapeutic effects are typically described over a period of months to years. Clinical studies track the effects over extended periods, sometimes as long as 15 years, to determine the full extent of the medicine's benefit.


Q: Does Novofen interact with common supplements like multivitamins?

Official drug information and specialized interaction checkers list potential interactions with certain herbal or high-dose supplements. These include agents like St. John's wort and high concentrations of Vitamin E, which have been documented to potentially reduce the drug's effectiveness.


Q: Is Novofen considered safe for the elderly population?

Official documents generally do not recommend a specific dose adjustment for older adults based on age alone. Official guidance notes caution for older adults with specific pre-existing conditions, such as reduced liver function.


Q: What are the major warnings listed in the Novofen patient leaflet?

The patient leaflets and regulatory documents highlight the potential for serious adverse risks. These major warnings consistently include the risks of developing uterine malignancies (such as endometrial cancer) and serious thromboembolic events, including stroke and pulmonary embolism.


Q: Can Novofen be split, crushed, or chewed?

Regulatory guidance advises that the tablets should be swallowed whole with a full glass of water. Official patient information states that the tablets are not intended to be chewed, crushed, or split.


Q: How is the safety of Novofen monitored after it is approved?

The safety of the medicine is continuously monitored through post-marketing surveillance by regulatory bodies and manufacturers. For individuals on treatment, safety is often assessed by routine blood tests to check liver function and blood cell levels.


Q: Is there a maximum daily amount of Novofen described in official labels?

Official labels provide clear boundaries for use. The maximum daily amount most commonly prescribed for established adult indications is 20 mg daily, though certain specialized regimens, such as for metastatic disease, may describe total daily doses up to 40 mg per day.


Q: Does Novofen interact with common cold or flu medicines?

Official interaction lists note that certain common ingredients found in cold or flu remedies may inhibit the CYP2D6 enzyme. This interaction has the potential to decrease the levels of the active metabolite of Novofen in the bloodstream, which may affect its overall effectiveness.


Q: How does Novofen compare to a placebo in clinical trials?

Clinical studies have shown that Novofen is associated with a significant reduction in the risk of breast cancer recurrence, death specifically related to the condition, and overall mortality when compared to a placebo or no treatment.


Q: Are there known cases of Novofen affecting lab test results?

Yes, regulatory documents indicate that the medicine can lead to changes in certain lab parameters. This includes documented reports of elevated liver enzyme levels and increased levels of fats in the blood (triglycerides), which are parameters that may be monitored during treatment.


Q: Is Novofen available as a generic version?

The active ingredient in Novofen, Tamoxifen, is widely available in a generic version in many regions worldwide. This generic availability is subject to national regulatory approval and patent status in each country.


Q: Can Novofen be taken on an empty stomach?

Official patient advice and product information state that the medicine can be taken with or without food. Official information emphasizes taking the medicine at a consistent time each day.


Q: Does Novofen cause weight gain or loss?

Regulatory documents list both weight gain and weight loss as reported side effects that have occurred during treatment. The relationship between the drug and these body weight changes is a common topic of study, but both are recognized possibilities.


Q: Is it normal to feel an initial stomach upset when starting Novofen?

Yes, regulatory documents list nausea (a feeling of sickness) as a very common side effect (ge 10%). Other gastrointestinal effects, such as vomiting and abdominal cramps, are also listed as common side effects that may be experienced when treatment is initiated.


Q: Is it normal to feel a mild headache after starting Novofen?

Official product information lists headache as a common side effect, meaning it is a recognized, frequent occurrence observed in patients taking the medicine. A mild headache is therefore a possibility that is consistent with the established safety profile.

How should Novofen be stored and disposed of?

The official regulatory documents provide clear instructions for the storage, handling, and disposal of Novofen (Tamoxifen oral tablets) to maintain product stability and ensure public safety.

Required Storage Conditions

Constraint Requirement (Regulatory Basis)
Temperature Range Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Avoid excessive heat above 40 C.
Environmental Protection Must be protected from light. Do not refrigerate or freeze.
Packaging Rule Keep the tablets in the original container and securely closed.
Child Safety Store out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Rules

Unused or expired Novofen must not be discarded in household trash or poured down a sink or toilet (wastewater). The official guidance recommends returning the product to a pharmacy or designated medicine take-back program for safe, controlled disposal, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novofen found in:

A-Z Index: